



Diagnósticos da América S.A.

Relações com Investidores
Av. Juruá, 434 - Alphaville, Barueri - SP
55 11 4197-5410
55 11 4197-5509
ir@danet.com.br
www.diagnosticosdaamerica.com.br



MATERIAL FACT

Diagnósticos da América S.A. Publicly-held Company Corporate Taxpayer's ID (CNPJ/MF) 61.486.650/0001-83

Pursuant to CVM Instruction 358/2002 and the current legislation, Diagnósticos da América S.A. (Bovespa: DASA3) informs its shareholders and the market that:

On May 24, 2007, Diagnósticos da América S.A. ("DASA") acquired 6,370,374 (six million, three hundred seventy thousand, three seventy-four) quotas representing 100% of the capital stock of Laboratório Exame Ltda., ("Exame"), which provides clinical analysis services in Brasília, Distrito Federal.

The quotas will be acquired for R\$ 56 million. Of the amount to be paid to Exame's former partners, R\$ 54 million will be paid upfront, in cash, with DASA's own funds, and the remaining R\$ 2 million will be retained in an escrow account for up to 6 years. On the acquisition date, Exame had a net cash position of R\$ 0.7 million. A portion of Exame quotas, representing 14.29% of the capital stock, was sold by the estate of a former partner of Exame, and the transfer of these quotas to DASA depends on a court authorization.

Laboratório Exame was founded in 1975 to provide clinical analysis services in Brasília (DF), where it is the second major player. According to a survey carried out by the Data Folha Institute in 2006, Exame is the laboratory most frequently recommended by doctors, with an overall recommendation of 91%. Certified by ISO 9001:2000, Exame currently has 19 units in this region, where it serves close to 33,000 patients monthly. In 2006, Exame's gross revenue totaled R\$38.8 million.

This acquisition strengthened DASA's position in the Federal District, where 32% of the population have private health plan, the third largest coverage in Brazil. The strategic planning foresees Exame as an executive brand, along with the opening of new units, the expansion of the *menu* of clinical analysis tests and the introduction of new imaging tests in the upcoming years.

The operation was approved at DASA's Board of Directors Meeting held on May 24, 2007. As the acquisition price amounts to a relevant investment for DASA, pursuant to Article 256, item I, Paragraph One of Law 6.404/76, it will be submitted to the approval of the Extraordinary Shareholders' Meeting to be held at an opportune moment. The acquisition of Exame will be submitted to the approval of the Administrative Council for Economic Defense (CADE).

São Paulo, May 24, 2007

Marcelo Marques Moreira Filho
CEO and Investor Relations Officer